Inivata Overview

  • Founded
  • 2014

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 85

Employees
  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $399M

Inivata General Information

Description

Developer of medical tests designed to detect cancer using liquid biopsies. The company's platform focuses on harnessing the potential of circulating tumor DNA (ctDNA) analysis, monitor response and detect relapse, enabling clinicians to make informed treatment decisions with respect to the treatment of cancer patients.

Contact Information

Website
www.inivata.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Parent Company
Primary Office
  • Glenn Berge Building
  • Babraham Research Campus, Babraham
  • Cambridge CB22 3FH
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inivata Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 18-Jun-2021 $399M 00000 00000 Completed Generating Revenue
6. Secondary Transaction - Private 15-Mar-2021 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 04-Feb-2021 000.00 00000 00000 Completed Generating Revenue
4. Later Stage VC 03-Jun-2020 000.00 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series B) 28-Mar-2019 000.00 00000 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 26-Jan-2016 $45.6M $52.2M 0000 Completed Generating Revenue
1. Early Stage VC 23-Sep-2014 $6.55M $6.55M 000 Completed Startup
To view Inivata’s complete valuation and funding history, request access »

Inivata Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C2 Preferred 0,000,000 00.000000 00.00 00.00 00.00 0.000
Series C2 Preferred 0,000,000 00.000000 00.00 00.00 00.00 0.000
Series C1 0,000,000 00.000000 00.00 00.00 00.00 0.000
Series C1 0,000,000 00.000000 00.00 00.00 00.00 0.000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00.00 0.000
Series A 16,591,575 $0.000014 7% $2.59 $2.59 $2.59 25.34%
Preference 4,000,000 $0.000014 5% $1.36 $1.36 $1.36 6.11%
To view Inivata’s complete cap table history, request access »

Inivata Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of medical tests designed to detect cancer using liquid biopsies. The company's platform focuses on harnessing
Diagnostic Equipment
Cambridge, United Kingdom
85 As of 2021
00000
0000 0000-00-00
000000&0 00000

000000

ore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offi
0000000000 000000000
Abingdon, United Kingdom
000 As of 0000
00000
0000 0000-00-00
000000&0 00000

000000

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000000000 000000000
Cambridge, United Kingdom
0 As of 0000
000.00
0.000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inivata Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxford Immunotec Formerly VC-backed Abingdon, United Kingdom 000 00000 000000&0 00000
0000000 Formerly VC-backed Cambridge, United Kingdom 0 000.00 000000&0 000.00
0000000 0000000000 Venture Capital-Backed Beverly, MA 00 00.00 0000000000 0 00.00
00000000000 Venture Capital-Backed Birmingham, AL 00 00.000 0000000000 0 00.000
00000000 Pending Transaction (M&A) Irvine, CA 000 000.00 000000000 000.00
You’re viewing 5 of 52 competitors. Get the full list »

Inivata Patents

Inivata Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202212094-D0 Method of detecting cancer dna in a sample Pending 19-Aug-2022
EP-4013894-A1 Method for altering therapy of advanced non-small cell lung cancer patients based on analysis of ctdna Pending 13-Aug-2019 0000000000
US-20220325356-A1 Method for altering therapy of advanced non-small cell lung cancer patients based on analysis of ctdna Pending 13-Aug-2019 0000000000
EP-3931356-A1 Method for quantifying the amount of a target sequence in a nucleic acid sample Pending 28-Feb-2019 0000000000
US-20190112645-A1 Method for measuring mutational load Active 21-Dec-2018 C12Q1/6827
To view Inivata’s complete patent history, request access »

Inivata Executive Team (21)

Name Title Board Seat Contact Info
Tim Shannon Chief Financial Officer & Secretary
Alan Schafer Ph.D Chief Technology Officer
Nitzan Rosenfeld Ph.D Co-Founder & Chief Scientific Officer
Jacqui Watson Chief of Staff
Tim Forshew Ph.D Co-Founder & Head, Science and Innovation
You’re viewing 5 of 21 executive team members. Get the full list »

Inivata Board Members (12)

Name Representing Role Since
Douglas VanOort NeoGenomics Laboratories Board Member 000 0000
Jeffrey Buchalter Self Non-Executive Chairman 000 0000
Peter Wrighton-Smith Ph.D Self Board Member 000 0000
You’re viewing 3 of 12 board members. Get the full list »

Inivata Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inivata Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cambridge Innovation Capital Venture Capital Minority 000 0000 000000 0
Cancer Research Horizons Venture Capital Minority 000 0000 000000 0
Farallon Capital Management Hedge Fund Minority 000 0000 000000 0
Future Planet Capital Growth/Expansion Minority 000 0000 000000 0
IP Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »